AMRI Files Motion for Preliminary Injunction Against Manufacturers and Sellers of Unlicensed Generic Fexofenadine.

ALBANY, N.Y. -- Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced that its wholly owned subsidiary, AMR Technology, Inc., along with Aventis Pharmaceuticals Inc. (a member of the sanofi-aventis Group) (NYSE: SNY), has filed a motion for a preliminary injunction in the United States District Court for the District of New Jersey seeking to enjoin Barr Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories, Ltd. and Amino Chemicals, Ltd. from the commercial production and distribution of generic fexofenadine products.

Beginning in 2001, Aventis Pharmaceuticals Inc. filed patent infringement actions in the United States District Court for the District of New Jersey against several generic pharmaceutical manufacturers based on patents relating to Sanofi-Aventis' ALLEGRA(R) and ALLEGRA-D(R) products. In March 2004, AMRI joined Aventis Pharmaceuticals Inc. in filing additional lawsuits pertaining to AMRI's fexofenadine-related patents, which are licensed to Aventis Pharmaceuticals Inc.

The motion for a preliminary injunction results from the September 6, 2005 announcement by Barr and Teva that they have entered into an agreement for the at-risk launch of generic versions of fexofenadine 30 mg, 60 mg and 180 mg tablets while the patent infringement actions against them are still pending.

Regardless of the outcome of the preliminary injunction motion, AMRI will continue to forcefully and vigorously defend its intellectual property.

Albany Molecular Research, Inc. is a chemistry-based drug discovery, development and manufacturing company. The company provides contract chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D.